NOA 2023: Bridging the gap between glaucoma news and patient care

Video

At NOA 2023, Monique Barbour, MD, caught up with Optometry Times to tell us more about her presentation on the latest and greatest in glaucoma.

Monique Barbour, MD, presented a talk entitled, "Glaucoma research and industry news: Potions and procedures," at National Optometric Association 2023 Convention in Fort Lauderdale, Florida.

Video transcript

Editor's note: This transcript has been edited lightly for clarity.

Monique Barbour, MD:
Hi everyone. I'm Dr. Monique Barbour. I'm a board-certified ophthalmologist in West Palm Beach, Florida.

My presentation was titled, "Glaucoma research and industry news: Potions and procedures." It was a very, very good talk, which included all the elements of everything new in glaucoma. We talked first about the types of glaucoma, and this led to a discussion on new medications, new laser treatments, clinical trials, and community outreach programs as well as access to medications and care for glaucoma patients.

I think one of the biggest things that we need to look at now is to take a look at all of the glaucoma studies and trials that are there. One other thing to add is to pay close attention to big data and artificial intelligence and see how it incorporates our treatment profile and management of our patients.

When it comes to the African American community, it's important to tag along with national observances, such as Juneteenth. To get the word out about glaucoma. The key takeaway points are to preserve the ocular surface with the use of preservative-free topical medications. Second, consider a laser treatment or surgical procedure earlier to preserve the best quality of life for our glaucoma patients. Always advocate for our patients' betterment.

I think that it's important to stay in the community and tag along, again, with some of the national observances, such as January: It is glaucoma month. During the month of March, we have a whole week that we commit to creating awareness and advocacy for our glaucoma patients. We certainly do need to keep those in mind. At the same time, we need to exploit all of the services that are available through the various glaucoma foundations and national programs that support our patients.

Recent Videos
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.